CR Bard buys majority interest in X-Trode:
This article was originally published in Clinica
CR Bard has bought a majority stake in Italian coronary stent manufacturer X-Trode. Chairman and CEO of Bard, William Longfield, says the purchase will provide Bard with a stainless steel coronary stent superior to those already on the market. Terms of the deal were not disclosed.